ReviewFrontiers in immunology2025
Research advances of pan-immune inflammation value in rheumatoid arthritis.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association between CALLY index and all-cause mortality in patients with rheumatoid arthritis.Frontiers in nutrition · 2026Article
- Immunological heterogeneity in rheumatoid arthritis: challenges in early-stage stratification, non-response to targeted therapy, and the restoration of immune tolerance.Frontiers in immunology · 2026Review
- Machine learning integrating immune-related cells, immunoglobulins, and immuno-inflammatory markers identifies risk factors for pulmonary comorbidities in ankylosing spondylitis: stratified analyses by chronic obstructive pulmonary disease and pulmonary nodules.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a persistent autoimmune condition marked by systemic inflammation, primarily impacting multiple joints and causing irreversible structural and functional damage. While pathophysiology remains complex, immune cells and cytokines are crucial to the disease's initiation and progression. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are routinely used to assess disease activity. However, in recent years, the pan-immune inflammatory value (PIV) has emerged as a focal point of inquiry. As a new, single biomarker calculated from various routine blood parameters, PIV accurately reflects the patient's comprehensive systemic immune-inflammatory condition and offers a more integrated perspective than traditional markers. This article provides a focused analysis of the potential role and clinical significance of PIV in assessing the activity and advancement of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.